Valneva SE
VALN · Price history
Price at last available close
$5.74
−$0.40 (-6.51%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Valneva SE
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria.
How they make money
Valneva SE is a specialty vaccine company that generates revenue primarily through the sale of its own proprietary prophylactic vaccines and through the distribution of third-party vaccines. The company also engages in research and development collaborations and licensing agreements for its vaccine candidates, which may involve upfront payments, milestone payments, and royalties.
Products & services
Valneva develops and commercializes prophylactic vaccines for infectious diseases, including its own proprietary vaccines and third-party products distributed through its commercial infrastructure.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company sells its products primarily through distributors and does not disclose specific major customer concentration in its 2025 annual filing.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production of its vaccine products and candidates.Source
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Quarterly revenue fell 26.5% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Diluted weighted-average shares increased 23.3% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
8
Poor
Financial Strength
24
Business Quality / Moat
0
Management
0
Growth Quality
0
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for VALN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving VALN's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can VALN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does VALN's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for VALN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify VALN's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Market Cap
$531.9M
P/E Ratio
-2.7
EPS
$-2.04
52-Week High
$12.18
52-Week Low
$4.75
Beta
1.35
Analyst Target
$14.00
Shares Outstanding
84.1M
Total Revenue
$160.9M
Total Debt
$235.6M
Dividend
No current dividend
Liquidation Value / Share
$1.08
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for VALN
Detected from reported data — verify before acting.Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on VALN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Specialized expertise in vaccine development and commercialization.
- +Established commercial infrastructure in multiple international markets.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on clinical trial success and regulatory approvals.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
10
Oct 1, 2026
Change
+0.1
points
Current Score
10
Oct 26, 2026
Category Changes
VALN increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
10
Projected Change
0.0 points
Preliminary comparable-period financial changes suggest little change. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$5.74
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160.9M | $195.8M | $190.1M | $172.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $134.6M | $120.1M | $110.5M | $113.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $26.3M | $75.7M | $79.6M | $59.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $93.4M | $95.6M | $83.1M | $67.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $72.0M | $83.7M | $106.6M | $108.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $156.5M | $167.2M | $64.7M | $151.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$104.5M | -$56.6M | $36.0M | -$64.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$130.2M | -$91.5M | $14.9M | -$92.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $45.6M | $47.0M | $26.9M | $26.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$177.2M | -$127.9M | -$12.9M | -$110.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $79K | $1.2M | $853K | $3.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$177.3M | -$129.1M | -$13.7M | -$113.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.04 | $-1.48 | $-0.19 | $-1.64 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 94.82M | 84.09M | 70.26M | 69.31M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 94.82M | 84.09M | 70.26M | 69.31M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$39.8M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.38
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+6.7%
Cash Change
-24.7%
Margin Change
-65.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 26.5%. EPS increased 126.7%. Cash declined 24.7%. Total debt increased 6.7%. Net income margin declined by 65.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Valneva Provides Update on IXCHIQ® in the United Kingdom
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Rumor Mill · VALN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial